Robotic assisted radical cystectomy: oncological safety

Area of Science:

• Urology
• Surgical Oncology
• Minimally Invasive Surgery

Background:

• Bladder cancer treatment necessitates rigorous quality assessment of surgical and pathological outcomes.
• Conventional open surgery and robotic-assisted laparoscopic radical cystectomy (RALRC) are key treatment modalities.
• Comparative analysis of quality parameters between different surgical approaches is crucial for optimizing patient care.

Purpose of the Study:

• To evaluate and compare quality parameters in bladder carcinoma treatment between the Bladder Cancer Collaborative Group (BCCG) and the International Robotic Cystectomy Consortium (IRCC).
• To assess surgical and pathological outcomes, focusing on margin status and lymphadenectomy, in patients undergoing radical cystectomy.

Main Methods:

• A comprehensive MEDLINE database search was conducted to identify relevant publications from BCCG and IRCC.
• Data on surgical margins and lymphadenectomy from selected studies were extracted and analyzed.
• Quality parameters were described and compared between the two consortia.

Main Results:

• Positive surgical margins were similar between IRCC (6.8%) and BCCG (6.5%), with no significant difference based on disease extent.
• Lymphadenectomy rates and the number of lymph nodes removed were generally higher in the IRCC series compared to BCCG.
• The learning curve for robotic surgery did not significantly impact surgical margin outcomes.

Conclusions:

• Robotic assisted laparoscopic radical cystectomy (RALRC) demonstrates comparable surgical margin quality to conventional open surgery.
• RALRC facilitates adequate pelvic lymphadenectomy, a critical component of radical cystectomy.
• Long-term oncological outcomes of RALRC require extended patient follow-up for definitive assessment.